PSI 938

Drug Profile

PSI 938

Alternative Names: PSI-352938; PSI-938

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmasset
  • Class Antivirals; Purine nucleotides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 17 Jan 2012 Pharmasset has been acquired by Gilead Sciences
  • 01 Jan 2012 Pharmasset completes a phase I trial in Hepatitis C in USA and Puerto Rico (NCT01497327)
  • 21 Dec 2011 Pharmasset initiates enrolment in a phase I trial to PSI-938 and PSI-7977 in Hepatitis C positive patients with hepatic impairment in the US and Puerto Rico (NCT01497327).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top